Health Care/Hospital
Nippon Express Obtains GDP Certification of Compliance with WHO Standards at East Japan Pharmaceutical Center
- Dedicated Pharmaceutical Logistics Facility Offers Storage and Transport in Two Temperature Ranges - TOKYO, Sept. 14, 2022 /PRNewswire/ -- Nippon Express Co., Ltd. (hereafter "Nippon Express"), a group company of NIPPON EXPRESS HOLDINGS, INC., has acquired Good Distribution Practice (GDP) cert...
Fosun: Foreign Media Reports about "Regulatory Authorities Asking Banks to Examine their Exposure to Fosun" are Completely False
HONG KONG, Sept. 14, 2022 /PRNewswire/ -- In response to foreign media reports about "Chinese regulatory authorities asking banks and some of the state-owned companies to examine their exposure to Fosun" on 13 September, Fosun said such reports are completely false. It is understood that Fosun h...
Data from KN046 in Patients with metastatic NSCLC who failed first line treatment or prior EGFR-TKIs Presented at ESMO 2022
* 64 patients with metastatic NSCLC who had failed first-line treatment were enrolled, the median follow-up was 21.6 months and the median OS was 18.40 month s,among 41 patients with non-squamous NSCLC, the median OS was 19.81 months, while among 20 patients with squamous NSCLC, the median OS wa...
Alphamab Oncology Presents the updated data from Phase 2 Clinical trial on KN046 Combined with platinum doublet chemotherapy as first-line(1L)treatment for NSCLC at ESMO 2022
* 2-year survival data of this study were presented: KN046 combined with platinum doublet chemotherapy showed promising efficacy and well tolerated safety as first-line(1L)treatment for advanced NSCLC patients * In 87 efficacy evaluable patients, confirmed ORR was 46%. * Median OS in non-squ...
Updated Data Presented for KN026 comboKN046 in 1st Line HER2-Positive Gastric/Gastroesophageal Junction Cancer (GC/GEJ)
* As of January 30, 2022,31 patients with HER2-positive unresectable locally advanced or metastatic GC/GEJ, with no prior systemic treatment, were enrolled. 27 patients were evaluable for efficacy. The ORR was 77.8% and DCR was 92.6%. * The phase III pivotal study is planned to confirm the eff...
Antengene Unveils Its First Australian Office to Continue Expanding Global Presence
SHANGHAI and HONG KONG, Sept. 14, 2022 /PRNewswire/ -- Antengene recently unveileda new office space situated in Melbourne, Australia's most sought-after CBD, taking another important step in the company's continued global expansion. The new office offers an appealing environment that will help An...
FWD announces update to bond consent solicitation and publication of half year results
HONG KONG, Sept. 14, 2022 /PRNewswire/ -- FWD Limited and FWD Group Limited – consolidated subsidiaries of FWD Group Holdings Limited ("FWD Group" or "the Company") – announced updates and additional information, including FWD Group's results for the six months ended30 June 2022, as part of annou...
Debiopharm Co-leads a 10M USD Series A Round to Accelerate the Development of Genomic Medicines through Artificial Intelligence
Debiopharm Innovation Fund strategically invests in Whitelab Genomics' mission to make genomic medicine development faster and leaner for more efficient access to cancer patients in the future LAUSANNE, Switzerland, Sept. 14, 2022 /PRNewswire/ -- Debiopharm Innovation Fund, the strategic investm...
TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism
BIRMINGHAM, England, Sept. 13, 2022 /PRNewswire/ -- Concept Medical
AnBogen Therapeutics Receives Approval from U.S. FDA for Phase Ib/II Protocol Amendment for ABT-101
An oral Tyrosine Kinase Inhibitor of HER2 Exon20 Insertion, for the Treatment of Non-Small Cell Lung Cancer TAIPEI, Sept. 13, 2022 /PRNewswire/ -- AnBogen Therapeutics, a clinical-stage biotech company designing and developing precision oncology therapies to improve the life of patients, announ...
Turn Biotechnologies launches eTurna™ delivery platform designed specifically to enable nucleic acid therapeutics
The proprietary platform is versatile, equally effective with different cargoes, routes of administration MOUNTAIN VIEW, Calif., Sept. 13, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today ann...
INDEPENDENT SCIENTIFIC STUDY DEMONSTRATES PFAS IS NOT IDENTIFIED OR LEACHED IN IPACKCHEM ADVANCED IN-MOLD FLUORINATED CONTAINERS
PARIS, Sept. 13, 2022 /PRNewswire/ -- An independent study designed and overseen by Environmental Standards, Inc. and conducted by Pace Analytical Services LLC found that no PFAS were identified or found to leach into the contents of IPACKCHEM's proprietary Advanced In-Mold Fluorinated (IMF) con...
AO Foundation acquires RIMASYS to advance the surgical education ecosystem of the future
DAVOS, Switzerland and COLOGNE, Germany, Sept. 13, 2022 /PRNewswire/ -- The AO
Foundation and RIMASYS are pleased to announce that they have taken their
strategic partnership to the next level with a full-stake investment by the AO
in RIMASYS.
TikoMed's ILB(R) inhibits cell infection by coronaviruses and modulates reactive cytokine release from microglia in vitro
Adds further support for its broad-spectrum mechanism of action following other recent TBI, ALS and tropical virus studies VIKEN, Sweden, Sept. 13, 2022 /PRNewswire/ -- TikoMed today announced the inclusion in bioRxiv* of an in vitro study evaluating the ability of the company's lead drug candid...
SmartFuture's White-label Remote Patient Monitoring Platform goes global
SINGAPORE, Sept. 13, 2022 /PRNewswire/ -- SmartFuture's white-label Remote Patient Monitoring (RPM) platform is now being deployed successfully in 11 countries, includingSingapore, Malaysia, other ASEAN countries, India and most recently, inthe United States. According to Sumit Khemani, CEO, "...
German Chancellor Scholz, WHO Director-General Tedros, international ministers at World Health Summit 2022
Press accreditation open for the world's leading global health conference BERLIN, Sept. 13, 2022 /PRNewswire/ -- The World Health Summit and the World Health Organization (WHO) as co-organizer jointly invite to the world's leading global health conference. The World Health Summit 2022 fromOctober...
Manulife appoints HyounJoo Choe as Chief Customer Officer for Hong Kong and Macau to spearhead customer experience and centricity
HONG KONG, Sept. 13, 2022 /PRNewswire/ -- Manulife Hong Kong today announced the appointment of HyounJoo Choe as Chief Customer Officer,Hong Kong and Macau. As a member of the senior management team, Ms Choe will lead all customer experience and strategic marketing functions including marketing, ...
Microtech to unveil implantable microsensor technology at 34th Transcatheter Cardiovascular Therapeutics (TCT) annual meeting
TEL AVIV, Israel, Sept. 13, 2022 /PRNewswire/ -- Microtech, a wholly owned subsidiary of Medinol, Inc., a leader in global MedTech research and development, announced that its implantable microsensor platform will be presented at the34th Transcatheter Cardiovascular Therapeutics (TCT), the annua...
CStone announces China's NMPA has accepted and granted priority review to the supplemental new drug application (sNDA) for sugemalimab in the treatment of patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL)
* This is the third supplemental new drug application (NDA) that CStone has submitted for sugemalimab after the prior two for stage III and IV non-small cell lung cancer. Sugemalimab has the potential to become the world's first immuno-oncology therapy to be approved for patients with relapsed ...
Transcenta Releases Encouraging Interim Safety and Efficacy Data of the TST001 (Osemitamab) and Chemotherapy Combination Expansion Cohort for First Line Claudin18.2 Positive Gastric Cancer at ESMO Congress 2022
* In first line treatment of advanced or metastatic G/GEJ cancer, early interim data of the first 15 patients with measurable disease receiving the combination of TST001 (Osemitamab) with CAPOX demonstrated a partial response rate of 73.3% and a disease control rate of 100% per RECIST1.1. * B...
Week's Top Stories
Most Reposted
Multiple achievements made in China-Hungary BRI conference
[Picked up by 319 media titles]
2024-05-03 06:59Shanghai Jiao Tong University Offers Free Online Courses for International Learners, Joint Programs with Tmall of Alibaba and Dow Gain High Popularity
[Picked up by 316 media titles]
2024-05-07 08:00Xinhua president, Hungarian economy minister vow to bolster media cooperation
[Picked up by 289 media titles]
2024-05-03 06:25TAILG Makes Grand Appearance at 2024 Asiabike Jakarta, Aiming to Set the Benchmark in Indonesia
[Picked up by 262 media titles]
2024-05-02 01:21China-Serbia forum highlights community with shared future for mankind
[Picked up by 245 media titles]
2024-05-01 11:39